High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition

Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H · Diabetes

Null at ten times the Timmers dose. Insulin sensitivity by clamp — the primary outcome — deteriorated insignificantly in both arms. Endogenous glucose production, glucose turnover and oxidation, blood pressure, resting energy expenditure, lipid oxidation, ectopic and visceral fat, and inflammatory and metabolic biomarkers were all unchanged. The authors wrote that the result 'raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders'.

Population

Obese but otherwise healthy men

Intervention

Resveratrol 1,500 mg/day for 4 weeks

Comparator

Placebo

Limitations

Twenty-four men, four weeks. Investigator-initiated and independently funded, at a high dose, with insulin sensitivity measured by clamp.